Lab21 unveils new services at Greenville site

Lab21 has announced the start of routine analysis of clinical samples from its new CLIA laboratory in Greenville, South Carolina.
The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service. Using the Roche COBAS 4800 HPV Genotyping test, Lab21 can identify high risk patients and differentiate those patients with HPV 16 and HPV 18 Genotypes.

The Lab21 service launches concurrently with new guidelines for the prevention and early detection of cervical cancer which were recently issued by the American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP).
 

Michael Bolick, President, Lab21 Inc said “Over recent months we have grown the Greenville team and worked closely with local clinicians to prioritise the menu of tests required by local hospitals. The final validation of these assays and the receipt of our first patient samples are the culmination of Lab21’s strong team work internationally. Our colleagues from the UK have developed best practices in molecular diagnostic testing that we have transferred, along with key individuals, into our US operations.”
 

Through its partnership with hospital-based cancer research organisation ITOR, a hospital based cancer Lab21 is planning development of new companion diagnostic assays required to accompany new drug therapies.

Ken Morgan, Vice President Operations, Lab21 Inc said “We welcome our new Laboratory Manager, Susan Foster, and Clinical Sequencing Group Leader, Jeremy Stuart to Lab21 Inc who are two very experienced clinical testing professionals from market leading companies. During the next 12 months we intend to grow our core team in Greenville rapidly as we add new test menu and launch our own companion diagnostic assays.”